Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pulmonology
•
Obstructive Lung Disease
•
Primary Care
What is your approach to de-escalation of asthma therapy if patients have remained clinically stable on triple inhaler therapy and a biologic agent?
Answer from: at Community Practice
Since the reason most folks need biologics is prednisone and considering the side effects, getting patients down to the lowest dose is beneficial.
Sign In
or
Register
to read more
23325
Related Questions
When do you consider switching from another biologic to benralizumab in patients with severe eosinophilic asthma with a history of suboptimal response to previous biologic agents?
What are the potential challenges and benefits of implementing z score thresholds in clinical practice for COPD severity classification, and how might this affect patient outcomes?
Are there benefits to adding IL5/IL5 receptor blockade in patients with vasculitic manifestations of EGPA?
How do you manage resistant infections that persist after stopping antibiotic therapy in patients with non-CF bronchiectasis?
How do you manage daytime somnolence without a clear cause?
How do you counsel patients who are concerned that discontinuation of certain chronic medications may actually perpetuate suffering at the end of life?
How do you manage persistent pseudomonas positive sputum a patient with non-CF bronchiectasis who has chronic sputum production but is otherwise asymptomatic?
Which patient characteristics or scenarios drive you to choose tezepelumab over dupilumab for asthma?
How do you decide the maximum amount of volume to remove during a therapeutic thoracentesis?
What is your preferred laboratory test to assess treatment response or infection resolution in patients with bacterial pneumonia?